By Alan Wookey, Scientific Advisor, Oncology, Q2 Solutions, a Quintiles Quest Joint Venture
The past decade has seen substantial growth and interest in immunotherapy research. Clinical technology must advance and expand ways to support sponsors as they race to find, develop and deliver immuno-oncology (IO) therapies to the growing number of patients who await them.
The Central Laboratory has been pivotal in testing and providing data that are needed to determine inclusion and exclusion criteria and to monitor safety profiles. Central labs contribute to the elucidation of responders versus non-responders (whether it be for efficacy, safety, or dosage) and use biomarkers for proof of mechanism of action or resistance and patient selection. Approvals for assays provided by central laboratories through their diagnostic offerings are also well documented.
Sponsors who partner with a global central laboratory should expect optimized outcomes resulting from a depth of immuno-oncology and technological expertise and harmonized processes.
Read this article to discover the power behind these central laboratories in immuno-oncology drug development.